Life Sciences AISeries BWorkflowℹAI-led scientific workflows can connect patient evidence to testable hypotheses, with biomedical experts and wet labs validating promising results.
Life Sciences AIAI-led scientific workflows can connect patient evidence to testable hypotheses, with biomedical experts and wet labs validating promising results. Owkin develops K Pro, an autonomous AI scientist that combines multimodal patient data, specialized agents, and laboratory validation to investigate biomedical questions.
Thomas Clozel
Co-founder
Gilles Wainrib
Co-founder
Editorial estimates from product descriptions. Model providers and actual usage are not confirmed.
Latest funding: Series B (aggregate disclosed) · $230M. Total raised: $304.1M.
Profile source review: 2026-11-04. Current official press kit lists Series B funding of $230M and total funding of $304.1M. These are disclosed aggregate figures on an undated page, not a single dated new financing announcement. No exact round date or lead investor is invented. Its 2022 Bristol Myers Squibb deal combines an equity investment with an upfront collaboration payment; the full $80M is not treated as pure equity. Current primary contact page lists the New York office. No global headquarters claim is made. Copy is synthesized from cited first-party messaging; no independent performance validation is implied.
Manhattan · verified office
119 West 24th Street, Floor 4, New York, NY 10011. Current company contact page explicitly lists New York among its office locations and supplies the street/floor. This is public business-contact evidence, not a legal filing or private address. Page is undated. No neighborhood or global-headquarters label inferred.
Contact Us - Owkin ↗Source checked 2026-11-04
Owkin is tagged workflow based on buyer clarity, repeat workflow activity, public activity, and fit with the AI Atlas map.
Hiring
5 roles from the company's careers page.
Updated 1h ago
Owkin is looking for a Customer Support Specialist to own first-level support for K-Pro, Owkin's AI research platform for biopharma R&D, used by AstraZeneca, Sanofi, Servier and Boehringer Ingelheim.
Owkin is looking for a sales professional to join our commercial team.
Owkin is looking for a sales professional to join our US commercial team, with a focus across pharmaceutical companies, biotech companies, CROs, VC/PE firms and selected investor-backed life sciences organizations.
We are seeking a highly skilled and experienced Scientist II Machine Learning Engineer to design, develop, and deploy cutting-edge AI solutions.
As a Software Engineer, you will build the world leading Agentic AI product for biomedical researchers by combining robust engineering practices with cutting-edge AI technologies.
Sign in to view job links
Roles are visible for signal. Apply links open after sign-in.
Proxima Bio, formerly VantAI, is an AI-native platform for proximity-based drug discovery, mapping protein-protein interactions to design medicines that reshape protein networks rather than inhibit single targets.
Life Sciences AIWorkflowℹ161viewsRecent Activity
Drug programs can be steered using continually updated evidence and probability-of-success estimates, helping identify patient subgroups and change course during trials.
Pathos AI develops oncology drugs using Foundry, an agentic platform that continuously analyzes clinical evidence to select assets and guide development decisions.
Life Sciences AIInfraℹRecent Activity
Scientific AI can become more useful by learning the mechanisms behind complex systems and using those explanations to guide new investigations.
Output Labs develops AI systems for mechanistic reasoning, aiming to model how complex systems work and apply those explanations to scientific problems.
Life Sciences AIWorkflowℹ115viewsRecent Activity
